**Core Concept**
Idiopathic primary pulmonary hypertension (IPPH) is a rare, progressive disease characterized by elevated pulmonary artery pressure without any identifiable cause. It involves the proliferation of endothelial and smooth muscle cells, leading to vascular remodeling and increased resistance in the pulmonary vasculature.

**Why the Correct Answer is Right**
The pathophysiology of IPPH involves the activation of various signaling pathways, including the endothelin-1 pathway, which promotes vasoconstriction and vascular remodeling. The disease is also characterized by an imbalance between vasodilators and vasoconstrictors, with a predominance of vasoconstrictive substances such as endothelin-1 and thromboxane A2. The proliferation of endothelial and smooth muscle cells in the pulmonary vasculature leads to the formation of plexiform lesions, which are a hallmark of the disease.

**Why Each Wrong Option is Incorrect**
* **Option A:** This option is incorrect because IPPH is not typically associated with atherosclerosis or atherosclerotic risk factors. While atherosclerosis can lead to pulmonary hypertension, it is not a characteristic feature of IPPH.
* **Option B:** This option is incorrect because IPPH is not typically associated with left-sided heart disease or left ventricular dysfunction. While left-sided heart disease can lead to pulmonary hypertension, it is not a characteristic feature of IPPH.
* **Option C:** This option is incorrect because IPPH is not typically associated with thromboembolic disease or pulmonary embolism. While pulmonary embolism can lead to pulmonary hypertension, it is not a characteristic feature of IPPH.

**Clinical Pearl / High-Yield Fact**
IPPH is often associated with a poor prognosis, with a median survival time of 2.5-3 years from diagnosis. Early diagnosis and treatment with vasodilators, anticoagulants, and other medications can improve survival and quality of life.

**Correct Answer:** None of the above